Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha More on Shell Shell Consolidates Its Upstream And LNG Position With ARC Resources Acquisition Shell: Refocusing Will Take Time (Probably A Few Years) Shell: The Company Should Be A Buy, But Near-Term Risks Warrant Patience Shell reports mixed Q1 results; gives Q2 and updates FY26 outlook...
Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha More on Shell Shell Consolidates Its Upstream And LNG Position With ARC Resources Acquisition Shell: Refocusing Will Take Time (Probably A Few Years) Shell: The Company Should Be A Buy, But Near-Term Risks Warrant Patience Shell reports mixed Q1 results; gives Q2 and updates FY26 outlook Shell earnings preview: Q1 profit seen surging 140%, investors weigh Middle East geopolitical risks
Earnings Call Insights: Biote (BTMD) Q1 2026 Management view CEO Bret Christensen said the quarter was shaped by the company’s operational work on clinic growth and support, but also by a voluntary recall-related disruption: “Over the past 12 months, we have made important progress to advance our strategic priorities. We have strengthened our commercial organization, expanded our sales team and en...
Earnings Call Insights: Biote (BTMD) Q1 2026 Management view CEO Bret Christensen said the quarter was shaped by the company’s operational work on clinic growth and support, but also by a voluntary recall-related disruption: “Over the past 12 months, we have made important progress to advance our strategic priorities. We have strengthened our commercial organization, expanded our sales team and enhanced our capabilities to better support practitioners and their patients.” Christensen tied Q1 performance pressure directly to the January voluntary withdrawal of certain pellet inventory: “This temporary supply disruption created a headwind to our first quarter performance, resulting in an estimated $1.7 million revenue impact and approximately $1.5 million of incremental costs incurred due to the voluntary recall.” He added the salesforce was diverted from growth: “The recall affected our first quarter results and was a significant distraction to our sales force and their growth objectives as they were forced to service accounts versus focusing on growth.” Christensen emphasized commercial capacity expansion despite the disruption: “I'm pleased to report that we are substantially complete with this effort with over 25 new sales personnel hired in the first quarter.” He also pointed to practitioner additions as a leading indicator: “In the first quarter, we trained more than 200 new practitioners, representing a 16.5% increase from the first quarter of 2025.” CFO Robert Peterson summarized the quarter’s financial pressure and mix shift: “Revenue decreased 8.3% to $44.9 million, with procedure revenue declining 13.2% to $31.3 million, which included a $1.7 million impact related to the voluntary recall of certain hormone pellets shipped by Asteria Health.” Outlook Peterson reiterated full-year targets while acknowledging a weaker first-half procedure cadence tied to the recall: “We maintain our guidance, forecasting 2026 revenue above $190 million and 2026 adjusted EBITD...
(RTTNews) - InterContinental Hotels Group PLC (IHG, IHG.L) reported Thursday very strong first-quarter trading performance, with growth of 4.4 percent in Global RevPAR.
(RTTNews) - InterContinental Hotels Group PLC (IHG, IHG.L) reported Thursday very strong first-quarter trading performance, with growth of 4.4 percent in Global RevPAR.
Angelini Pharma has agreed to acquire all outstanding shares of Catalyst Pharmaceuticals ( CPRX ) for $31.50 per share in cash, for a total equity value of approximately $4.1B. The deal has been unanimously approved by the boards of directors of both companies and is expected to close in the third quarter of 2026. The consideration represents a premium of 28% to Catalyst’s 30-day volume-weighted a...
Angelini Pharma has agreed to acquire all outstanding shares of Catalyst Pharmaceuticals ( CPRX ) for $31.50 per share in cash, for a total equity value of approximately $4.1B. The deal has been unanimously approved by the boards of directors of both companies and is expected to close in the third quarter of 2026. The consideration represents a premium of 28% to Catalyst’s 30-day volume-weighted average trading price as of April 22, 2026. Founded in 2002 and listed on Nasdaq since 2006, Catalyst has built a portfolio of products focused on the treatment of rare neuromuscular and neurological diseases. Following completion of the acquisition, Angelini Pharma plans to integrate Catalyst’s portfolio and commercial infrastructure with its own expertise and products in Brain Health to develop a next-generation therapeutic platform in Rare Diseases. The transaction will be carried out with the participation of Blackstone ( BX ) funds and select international partners, and will be financed with the support of BNP Paribas. CPRX shares fell 1.9% premarket on Thursday. More on Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma Catalyst forecasts 21–26% FIRDAPSE revenue growth in 2026 while expanding AGAMREE market penetration
(RTTNews) - ENGIE (ENGI.PA) reported first quarter EBITDA of 4.7 billion euros, down 13.6% on a gross basis and down 12.3% on an organic basis. EBITDA ex. Nuclear was 4.6 billion euros, was down 6.0% on a gross basis and down 4.4% on an organic basis. EBIT ex. Nuclear was at 3.4
(RTTNews) - ENGIE (ENGI.PA) reported first quarter EBITDA of 4.7 billion euros, down 13.6% on a gross basis and down 12.3% on an organic basis. EBITDA ex. Nuclear was 4.6 billion euros, was down 6.0% on a gross basis and down 4.4% on an organic basis. EBIT ex. Nuclear was at 3.4
Vonovia SE press release ( VONOY ): Q1 Non-GAAP EPS of €0.43. Revenue of €1.26B (+0.8% Y/Y). More on Vonovia SE Vonovia: Long Idea With Attractive Dividend Yield And Solid Future Returns Vonovia: Recent Pullback Provides A Buying Opportunity Vonovia SE 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Vonovia SE Historical earnings data for Vonovia SE
Vonovia SE press release ( VONOY ): Q1 Non-GAAP EPS of €0.43. Revenue of €1.26B (+0.8% Y/Y). More on Vonovia SE Vonovia: Long Idea With Attractive Dividend Yield And Solid Future Returns Vonovia: Recent Pullback Provides A Buying Opportunity Vonovia SE 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Vonovia SE Historical earnings data for Vonovia SE
Visualizing The Stunning Global Fertility Divide A widening gap is emerging in global birth rates. This chart, via Visual Capitalist's Niccolo Conte, shows population-weighted total fertility rates (TFR) across major world regions, based on data from the UN World Population Prospects 2024 Revision , and how they compare to the 2.1 replacement level. While Africa remains far above this threshold, m...
Visualizing The Stunning Global Fertility Divide A widening gap is emerging in global birth rates. This chart, via Visual Capitalist's Niccolo Conte, shows population-weighted total fertility rates (TFR) across major world regions, based on data from the UN World Population Prospects 2024 Revision , and how they compare to the 2.1 replacement level. While Africa remains far above this threshold, most of the world, including Asia, Europe, and the Americas, has already fallen below it. This split highlights where future population growth is likely to be concentrated. Africa Stands Apart Africa’s fertility rate of 4.0 children per woman is the highest of any region. It is nearly double the global average of 2.2 and close to three times Europe’s rate of 1.4. With a rapidly growing population base, Africa is expected to drive a significant share of global population growth in the coming decades. Higher fertility rates are often linked to younger populations, lower urbanization, and differences in access to education and healthcare. Below Replacement in Most Regions Many parts of the world now have fertility rates below the replacement level of 2.1. Asia, North America , and South America each sit at 1.7, while Europe trails at 1.4. These levels point to aging populations, slower natural population growth, and potential workforce pressures over time. In many countries, immigration and family-support policies are becoming more important parts of the demographic outlook. Population Weight Matters Asia accounts for 54% of the global population, meaning its relatively low fertility rate has an outsized influence on the global average. By contrast, regions like Oceania and the Middle East have higher fertility rates but much smaller populations. This helps explain why the global average remains at 2.2 even as most major regions fall below replacement. If you enjoyed today’s post, check out When Will the Global Population Reach Its Peak? on Voronoi , the new app from Visual Cap...